Palvella Therapeutics (PVLA) Operating Income (2013 - 2026)
Palvella Therapeutics (PVLA) reported Operating Income of -$14.9 million for Q1 2026, down 88.73% year-over-year from -$131.8 million in Q1 2025, and down 180.13% on a QoQ basis from $18.5 million in Q4 2025.
Palvella Therapeutics (PVLA) has 14 years of Operating Income data on file, last reported at -$14.9 million in Q1 2026.
- Quarterly Operating Income fell 88.73% year-over-year to -$14.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$15.7 million (up 22.09% YoY) and the FY2025 annual result came in at -$8.8 million, up 37.85% from the prior year.
- Operating Income fell to -$14.9 million in Q1 2026 per PVLA's latest filing, from $18.5 million in the prior quarter.
- Across five years, Operating Income topped out at $18.5 million in Q4 2025 and bottomed at -$15.5 million in Q1 2023.
- The 5-year median for Operating Income is -$7.7 million (2022), against an average of -$5.1 million.
- Peak annual rise in Operating Income reached 524.6% in 2025, while the deepest fall reached 347.47% in 2025.
- Tracing PVLA's Operating Income over 5 years: stood at -$12.2 million in 2022, then jumped by 210.01% to $13.4 million in 2023, then plunged by 132.62% to -$4.4 million in 2024, then jumped by 524.6% to $18.5 million in 2025, then sank by 180.13% to -$14.9 million in 2026.
- Per Business Quant, the three latest PVLA Operating Income figures stand at -$14.9 million (Q1 2026), $18.5 million (Q4 2025), and -$10.2 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.97 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -15.76 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 642.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 268.64 Mn |
| 10 | Palvella Therapeutics | 1.47 Bn | 1.21 Bn | - | -14.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.86 Mn |
| Dec 31, 2025 | 18.54 Mn |
| Sep 30, 2025 | -10.18 Mn |
| Jun 30, 2025 | -9.25 Mn |
| Mar 31, 2025 | -7.87 Mn |
| Dec 31, 2024 | -4.37 Mn |
| Sep 30, 2024 | -5.06 Mn |
| Jun 30, 2024 | -2.91 Mn |
| Mar 31, 2024 | -1.76 Mn |
| Dec 31, 2023 | 13.39 Mn |
| Sep 30, 2023 | -11.81 Mn |
| Jun 30, 2023 | 2.06 Mn |
| Mar 31, 2023 | -15.51 Mn |
| Sep 30, 2022 | -12.17 Mn |
| Jun 30, 2022 | -12.33 Mn |
| Mar 31, 2022 | -7.46 Mn |
| Dec 31, 2021 | -11.00 Mn |
| Sep 30, 2021 | -19.01 Mn |
| Jun 30, 2021 | -16.76 Mn |
| Mar 31, 2021 | -5.06 Mn |
| Dec 31, 2020 | -12.41 Mn |
| Sep 30, 2020 | -13.00 Mn |
| Jun 30, 2020 | -4.66 Mn |
| Mar 31, 2020 | -3.86 Mn |
| Dec 31, 2019 | -1.33 Mn |
| Sep 30, 2019 | -2.91 Mn |
| Jun 30, 2019 | -12.23 Mn |
| Mar 31, 2019 | -10.68 Mn |
| Dec 31, 2018 | -12.65 Mn |
| Sep 30, 2018 | -7.80 Mn |
| Jun 30, 2018 | -2.24 Mn |
| Mar 31, 2018 | -8.14 Mn |
| Dec 31, 2017 | 6.49 Mn |
| Sep 30, 2017 | -5.18 Mn |
| Jun 30, 2017 | -7.89 Mn |
| Mar 31, 2017 | -8.01 Mn |
| Dec 31, 2016 | -6.40 Mn |
| Sep 30, 2016 | -6.18 Mn |
| Jun 30, 2016 | -5.80 Mn |
| Mar 31, 2016 | -4.38 Mn |
| Dec 31, 2015 | -2.57 Mn |
| Sep 30, 2015 | -3.88 Mn |
| Jun 30, 2015 | -3.53 Mn |
| Mar 31, 2015 | -3.70 Mn |
| Sep 30, 2014 | -1.84 Mn |
| Jun 30, 2014 | -2.77 Mn |
| Mar 31, 2014 | -671,217.00 |
| Dec 31, 2013 | -2,198.00 |
| Sep 30, 2013 | -5,762.00 |
| Jun 30, 2013 | -274.00 |